Showing results (11-20 of 104) with videos related to
Sort By:
Pageof 11
Frontiers in Bioscience (Landmark Edition)|March 11, 2009
SH2 domain binding to phosphopeptide ligands: potential for drug targetingMoses M Kasembeli, Xuejun Xu, David J TweardyInternational Journal of Molecular Sciences|September 27, 2025
Update on Structure and Function of SH2 Domains: Mechanisms and Emerging Targeting StrategiesMoses M Kasembeli, Jorge Rodas, David J TweardyClinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 2, 2011
Severe pulmonary involvement in a case attributed to domestically acquired Seoul hantavirus in the United StatesIngrid L Roig, Daniel M Musher, David J TweardyJournal of Immunology (Baltimore, Md. : 1950)|February 24, 2006
Unique structural determinants for Stat3 recruitment and activation by the granulocyte colony-stimulating factor receptor at phosphotyrosine ligands 704 and 744Huang Shao, Xuejun Xu, Naijie Jing, et al.Journal of Structural Biology|February 23, 2013
WITHDRAWN: Intrinsic molecular characteristics of inhibiting STAT3 activation and dimerization through targeting the phosphotyrosine binding site within the SH2 domain-A molecular dynamics studyYubo Fan, Ren Kong, David J Tweardy, et al.Pharmacological Reviews|March 22, 2020
Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and CautionUddalak Bharadwaj, Moses M Kasembeli, Prema Robinson, et al.Scientific Reports|February 5, 2013
Modulation of the unfolded protein response during hepatocyte and cardiomyocyte apoptosis in trauma/hemorrhagic shockStephen A Thacker, Prema Robinson, Adam Abel, et al.International Journal of Molecular Sciences|August 8, 2018
Contribution of STAT3 to Inflammatory and Fibrotic Diseases and Prospects for its Targeting for TreatmentMoses M Kasembeli, Uddalak Bharadwaj, Prema Robinson, et al.Cancer Research|July 23, 2003
Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptorHuang Shao, Haiyun Y Cheng, Richard G Cook, et al.Critical Care Medicine|March 8, 2006
Interleukin-6 treatment reverses apoptosis and blunts susceptibility to intraperitoneal bacterial challenge following hemorrhagic shockAyse Akcan Arikan, Bi Yu, Mary-Ann Mastrangelo, et al.Pageof 11